Two key FDA officials to retire, leaving three divisions without permanent leaders

WASHINGTON — Two Food and Drug Administration directors will retire this week, according to the agency.

The departures leave three of the FDA’s 19 drug review divisions without permanent leaders.

Dr. Curtis Rosebraugh, who runs an office that oversees three drug review divisions, will be leaving the FDA. Also retiring is Dr. Donna Griebel, who directs the division that reviews drugs for gastrointestinal disease and some metabolic diseases. Both are retiring effective Saturday; neither returned a request for comment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In